In experimental diabetic cardiomyopathy models, trientine has been demonstrated to increase superoxide dismutase-1 (cytosolic SOD1) and superoxide dismutase-3 (SOD3, also known as extracellular SOD and EC-SOD) expression [34,38,42] (Table 4) (Figure 2). Here, SOD1 is linked to diabetic cardiomyopathy.